About
ZOLL TherOx is a division of ZOLL Medical Corporation, part of the Asahi Kasei Group, that specializes in advanced therapies for acute myocardial infarction, particularly severe heart attacks. The company focuses on SuperSaturated Oxygen (SSO2) Therapy, an FDA-approved treatment designed to reduce heart muscle damage after primary percutaneous coronary intervention (PCI) in patients experiencing left anterior descending ST-segment elevation myocardial infarction (LAD STEMI). The SSO2 Therapy System delivers a one-time, 60-minute infusion of super-oxygenated blood directly to the ischemic heart tissue immediately after PCI. This innovative approach improves microvascular flow and restores oxygen levels to damaged heart muscle. ZOLL TherOx primarily serves interventional cardiologists and hospitals, enhancing clinical outcomes for patients with severe heart attacks. In addition to SSO2 Therapy, ZOLL offers a wide range of medical devices and software solutions for emergency care, including defibrillators and cardiac monitors, supporting healthcare professionals in critical situations.
Technologies
Keywords
Company Information
- Employees37
- Founded1995
- Annual Revenue$4100000
- Total Funding$53441512
Location
2000 Ringwood Ave, San Jose, California, United States, 95131-1728
